About: TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.
Sector: Healthcare
Industry: Biotechnology
Latest price: $58.08 (+1.18%)
TGTX NASDAQ TG Therapeutics Inc
TG Therapeutics Inc share price
Atividade de preço de TGTX
Último preço
$ 58,080
Variação (24h)
0,68 USD (1,18%)
Volume
1.78M
Volume (média 4 sem.)
-
Abertura
$ 57,81
Variação do dia
$ 56,93 - $ 58,96
Fechamento anterior
$ 57,40
Último negócio
29 Oct, 8:00 pm GMT+0
Atrasado
29 Oct, 8:00 pm GMT+0
TGTX price performance
Atrasado
29 Oct, 8:00 pm GMT+0
quote.marketSignals